MedStar Health

Cardiac Surgery

MedStar Union Memorial Hospital

MedStar Union Memorial Hospital Chief of Cardiac Surgery Brian T. Bethea, MD (seated), with Cardiac Surgeons Ricardo O. Quarrie, MD (center), and Rachel E. Harrison, MD (right)

MedStar Union Memorial Hospital

Cardiac Surgery

At MedStar Union Memorial Hospital, we offer customized therapies for the most complex cases—often patients who have been denied care elsewhere. Using a multidisciplinary team approach, together with our interventional cardiology colleagues, we assess each patient to determine the best technology and access method—open, transcatheter, or hybrid—for their individual needs, priorities, and risk profiles.

Our aim is to provide your patients with the most effective treatment option, a low complication rate, a low readmission rate, and a safe, quick recovery.

Please see a brief snapshot of our FY 2022 key outcomes inside.





Aortic valve replacement

Our team treats complex aortic cases with the full spectrum of available options—including open, minimally invasive, and transcatheter approaches. We are also involved in a variety of studies to expand options to a broader population.

Aortic valve replacement + CABG

100% Absence of operative mortality

STS average 96.02 %

91.7% Absence of major morbidity

STS average 83.23%

8.3% Readmitted within 30 days of discharge

STS average 10.9 %

99.4% Absence of in-hospital TAVR mortality

Isolated aortic valve replacement

100% Absence of operative mortality

STS average 97.8 %

100% Absence of major morbidity

STS average 89.93%

0% Readmitted within 30 days of discharge

STS average 8.31%

Fiscal year 2022 data

Coronary artery bypass graft (CABG)

Coronary artery bypass graft (CABG) surgery remains the most common cardiac surgical intervention, but it has become much more difficult and nuanced due to increasing patient age and comorbidities and the frequency of prior procedures. Our surgeons have specialized training, advanced knowledge, and can offer customized solutions based on the complexity of each case.

98.9% Absence of operative mortality

STS average 97.54%

95.1% Absence of major morbidity

STS average 89.42%

4.9% Readmitted within 30 days of discharge

STS average 9.09%

The Society of Thoracic Surgeons

★★★

CABG

Coronary Artery Bypass Grafting

Three stars represents the highest achievable metrics in the U.S.



Mitral valve repair and replacement

Drawing from the collective expertise of cardiac surgeons, interventional cardiologists, and advanced cardiac imaging specialists, the treatment options for mitral valve conditions continue to be expanded. Our surgeons are experts in complex mitral valve repair, multiple reoperations, minimally invasive valve repair and replacement, and transcatheter repair and replacement.

Mitral valve regurgitation (MR) is the most prevalent valvular disease in the U.S. Our team is focused on expanding options for treatment, including interventions for the management of mitral annular calcification (MAC), a complex and often difficult-to-treat diagnosis.

Mitral valve repair and replacement

9.7% Major complications or operative mortality–observed

10% Readmitted within 30 days of discharge

Fiscal year 2022 data

Arrythmia surgery

Convergent AFib ablation is a minimally invasive, two-part ablation procedure that uses heat to stop the erratic electrical signals that cause AFib and restore a normal heart rhythm. A cardiac surgeon performs the first procedure by making a small incision under the breastbone, to create access to the heart and then creates lesions on the back walls of the heart. An electrophysiologist then gains access to the inside of the heart and blood vessels through the groin, to deliver therapeutic energy to areas of the heart to destroy the abnormal electrical activity.

We are seeing excellent outcomes at this point–more than 70 percent of patients remain free of AFib and related symptoms a year after their procedure.

27

Convergent ablation procedures

Highest volume hospital in Maryland



Research highlights

Our program serves as a clinical testing site for many major U.S. trials for valve repair and replacement solutions. Drawing from the collective expertise of cardiac surgeons, interventional cardiologists, and advanced cardiac imaging specialists, we continue to expand treatment options for mitral, tricuspid, and aortic valve conditions.

The following studies are ongoing. In many cases, we are the only participating site in Maryland.



Mitral valve

- The Tendyne™ transcatheter mitral valve replacement system as an alternative to open-heart surgery, for which we are one of the highest enrollers in the country for its safety and efficacy trial.
- The SAPIEN™ M3 System in patients with severe symptomatic mitral regurgitation for whom open or transcatheter treatment options are not recommended.

Tricuspid valve

- The TriClip, evaluating transcatheter clip repair for symptomatic patients with severe tricuspid regurgitation who are at higher surgical risk for tricuspid valve surgery.
- The CorMatrix® Cor ECM® Tricuspid Valve replacement, currently in an early feasibility study.



Aortic valve

- The SAPIEN™ X4 Transcatheter Heart Valve, being evaluated for safety and efficacy in subjects with symptomatic, severe, calcific aortic stenosis.

In addition to these trials, our ongoing participation in national registries enhances our ability to track quality metrics and stay current with benchmarks established for other high-performing programs. Current registry participation includes those for TAVR, TMVR, PCIs, and LAAOs.

Contact us

To discuss a case with our physicians, please call **410-554-6550.**

For more information on our program, please feel welcome to contact:

Brian Bethea, MD, Chief, Cardiac Surgery at 214-244-8787 or brian.t.bethea@medstar.net.

Fiscal year 2022 data

MedStar Health

110 Irving St., NW
Washington, DC 20010

MedStar Heart & Vascular Institute

Nationally recognized excellence in the Baltimore-Washington region

MedStar Heart & Vascular Institute is a national leader in the research, diagnosis, and treatment of cardiovascular disease, and has been recognized by *U.S. News & World Report* and The Society of Thoracic Surgeons as one of the top cardiovascular programs in the nation. MedStar Heart & Vascular Institute and the Cleveland Clinic Heart, Vascular & Thoracic Institute, the nation's #1 heart program, enjoy a robust clinical and research relationship based on shared expertise. Patients benefit from rapid-cycle quality improvements and the latest treatment protocols.

Referring physicians have access to recognized national leaders in multiple cardiac and vascular sub-specialties and local access to MedStar Heart & Vascular Institute cardiac and vascular physicians located throughout Maryland, Northern Virginia, and the Greater Washington, D.C. regions.

For more information or to make an appointment or referral, visit **MedStarHealth.org/Services/Cardiac-Surgery.**